A 5-day-old girl, born at term after an uncomplicated pregnancy, was admitted to the hospital after a routine midwife check showed that she had lost 15% of her original birth weight [6.2 lb (2.83 kg)]. She was being fed normal-term formula milk, and an initial assessment revealed only mild dehydration. The working diagnosis was a feeding problem, and her management plan was to be fed 150 mL/kg formula milk per day with regular monitoring of weight. The patient's serum concentrations of selected analytes were as follows: sodium, 135 mEq/L (135 mmol/L; reference interval, 135-145 mmol/L); potassium, 5.3 mEq/L (5.3 mmol/L; reference interval, 3.5-5.3 mmol/L); and urea, 11.7 mg/dL (4.2 mmol/L; reference interval, 3.5-6.5 mmol/L).
DISCUSSION WEIGHT LOSS IN A NEONATE
Some weight loss is normal in the first few days of life. A loss of up to 10% can be normal in breast-fed babies, but a weight loss of only 5% is expected in formula-fed babies (1 ) . Babies with excess weight loss in the context of difficulty establishing feeding-especially breast-fed infants-may show evidence of hypernatremic dehydration due to loss of body sodium, but with a greater deficit in body water (2 ) . In this case, the hyponatremia did not correlate with the clinical scenario for a formula-fed baby failing to gain weight, despite the patient following a clear feeding plan.
There are many pathologic causes (3 ) for faltering growth in an infant, including the following: genetic and chromosomal abnormalities, such as trisomy 21, Turner syndrome, and cystic fibrosis; inborn errors of metabolism; endocrine disorders, such as congenital adrenal hyperplasia (CAH) 3 ; anatomic abnormalities, such as a large ventricular septal defect or biliary atresia; and psychosocial factors (3 ), such as emotional deprivation, poverty, neglect, and maternal mental illness.
HYPONATREMIA AND HYPERKALEMIA IN THE NEONATE
This combination in association with excessive weight loss indicates a problem with sodium chloride metabolism. CAH due to salt-wasting 21-hydroxylase deficiency (SW21-OHD) is the most common cause of hyponatremia and hyperkalemia in neonates. SW21-OHD presents with virilization in the female neonate, but rarer inborn errors of adrenal steroid metabolism, such as steroidogenic acute regulatory protein deficiency, may not. Other causes include adrenal hypoplasia, cystic fibrosis, cerebral salt-wasting syndrome, and secondary causes of aldosterone insensitivity in such conditions as urinary tract infections, pyelonephritis, and obstructive uropathy (4 ).
INVESTIGATIONS TO RULE OUT OTHER CAUSES
The urine sodium concentration is helpful because it confirms renal salt wasting if it is inappropriately high. If the renal function is normal, renin and aldosterone tests should be requested. A low serum aldosterone result is seen in primary adrenal insufficiency. In the absence of excessive virilization, normal results for random serum cortisol, adrenocorticotropic hormone stimulation, testosterone, 17-hydroxyprogesterone, and aldosterone exclude CAH due to SW21-OHD. In suspected cases of other inborn errors of adrenal metabolism, a urine steroid profile is crucial to confirm the site of the block in order to direct future genetic mutation testing. Cystic fibrosis may present with low sodium concentrations. Such testing is included in the UK newborn-screening test and is indicated by an increased concentration of immunoreactive trypsinogen. The sweat test, however, remains the gold standard to confirm the diagnosis.
Secondary causes of aldosterone insensitivity, such as a urinary tract infection, are excluded by a normal urine microscopy result, and culture and a normal renal ultrasound scan will exclude an obstructive uropathy. Cerebral salt wasting shows an excessively high urinary sodium concentration, Ͼ100 mmol/L (4 ).
PATIENT FOLLOW-UP
The increased renin and aldosterone concentrations in the presence of hyponatremia and hyperkalemia were consistent with a diagnosis of pseudohypoaldosteronism type 1 (PHA1). The low urine sodium result seen in this case does not exclude renal salt wasting, because of the dilutional effect in a random sample. Fractional excretion of sodium is more specific because it is not affected by urine volume.
PATHOPHYSIOLOGY OF PHA
PHA comprises a collection of rare electrolyte imbalance disorders due to aldosterone (mineralocorticoid) resistance (5 ) . Renin is produced in response to hypovolemia, and aldosterone secretion (under stimulation from angiotensin II) is augmented in the presence of hyperkalemia. The biochemical abnormalities of PHA can be explained by the functions of aldosterone. Aldosterone crosses the plasma membrane of epithelial cells and binds to the cytosolic mineralocorticoid receptor. The receptor-hormone complex activates intracellular signaling cascades, increasing the luminal epithelial sodium channels in many organs, including kidney, lung, colon, and sweat and salivary glands. These channels control sodium absorption at the luminal surfaces of epithelial cells (5-7 ) . Sodium is then secreted at the basolateral surface into extracellular space via the Na ϩ -K ϩ ATPase pumps. This process is coupled with potassium secretion at the luminal surface. Therefore, epithelial sodium channel dysfunction leads to hyponatremia and hyperkalemia.
TYPES OF PHA
There are 3 types of PHA (Table 1 ). PHA1 has 2 clinical subtypes, each with a distinct pattern of inheritance. Type 2 is characterized by hypertension and hyperkalemic metabolic acidosis with low renin and aldosterone values (4, 8 ) ; it is therefore excluded in the present case. Type 3 is an acquired variety (4 ), in which transient aldosterone insensitivity is seen in such conditions as urinary tract infection, obstructive uropathy, or pyelonephritis. Type 3 PHA resolves with the resolution of the initial clinical condition. In our case, urine microscopy and renal ultrasound scan results were normal.
GENETICS OF PHA1
The autosomal recessive PHA1 is caused by mutations within the genetic subunits that code for the epithelial sodium channel (5) (6) (7) 9 ) . It is the most severe form, because the salt wasting occurs in numerous mineralocorticoid-sensitive tissues, including the lungs, kidneys, colon, and sweat and salivary glands. These patients require lifelong salt-replacement therapy.
Autosomal dominant PHA1 is the likely explanation for the case described. Salt wasting is restricted to the kidneys, and the mutation lies in the gene encoding the mineralocorticoid receptor (9, 10 ) . The mineralocorticoid receptor mutation leads to a lack of renal sensitivity to aldosterone, and the prognosis is better than for autosomal recessive PHA1. Genetic testing is available for PHA, but such testing is possibly more of academic interest. Genetic testing was not done in our case in light of a clear clinical diagnosis and a good response to sodium chloride supplementation. There was no known family history of the disease. difficulties, vomiting, and dehydration. Laboratory findings include hyponatremia, hyperkalemia, and metabolic acidosis. The glomerular filtration rate is normal, but it is rarely measured in infants. Hypovolemia and hypotension may also occur (4, 7 ) . These presenting symptoms are similar in infants with true hypoaldosteronism and CAH.
MANAGEMENT OF RENAL PHA1
In the acute phase, the neonate may need treatment for hypovolemic shock or correction of hyperkalemia and metabolic acidosis (4 ) . It may be necessary to treat the baby with steroids before confirmation of the PHA diagnosis, because a similar clinical picture can be caused by the salt-losing crisis of CAH.
Long-term treatment involves judicious fluid management and sodium chloride supplementation. After sodium chloride supplementation is initiated, the potassium concentration will normalize. The adequacy of supplementation can be measured by monitoring the serum potassium concentration (4 ); however, the plasma renin concentration gives the best estimate of salt replacement and should be measured every 3 to 12 months, depending on age. Total suppression will be seen with excessive sodium chloride replacement, and there may be no other clinical or biochemical indicators.
PROGNOSIS
In autosomal dominant PHA1, the renal tubules mature throughout infancy and urinary sodium wastage gradually decreases, with remission occurring by about 2 years of age because the child will take an adequate amount of salt in the diet by this age. The prognosis is very good (5 ), with resolution of the electrolyte disturbances. Symptoms may recur at times of sodium chloride restriction and during periods of illness or heat stress.
PATIENT OUTCOME
Regular sodium chloride supplementation (3 mmol/kg per day) was started on day 12, and weight gain was noted from day 21. The patient's serum sodium and potassium concentrations remain normal. At 10 months of age, she is growing normally, and her weight has increased from the 0.4th centile to the 75th centile. 
POINTS TO REMEMBER
• Excessive neonatal weight loss may be associated with hypernatremic dehydration in breast-fed babies.
• Hyponatremia in a neonate with clinically important weight loss warrants further investigation to consider less common endocrine causes, such as PHA or CAH.
• PHA1 may present symptomatically before the development of electrolyte abnormalities.
• PHA1 (autosomal dominant) is managed by sodium supplementation and monitoring of serum sodium and potassium concentrations.
